Peptide Database

86 therapeutic peptides with research summaries, clinical findings, and regulatory status.

Showing 11 peptides with status In Clinical TrialsClear filters
RecoveryIn Clinical Trials

TB-500 (Thymosin Beta-4)

Thymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue repair. It promotes wound healing by upregulating cell-building proteins such as actin and laminin, facilitating cell migration to sites of injury. TB-500 also has anti-inflammatory properties mediated through NF-kB pathway modulation.

Subcutaneous injection
MetabolicIn Clinical Trials

Retatrutide

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.

Subcutaneous injection (weekly)
HormoneIn Clinical Trials

CJC-1295

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.

Subcutaneous injection
HormoneIn Clinical Trials

Ipamorelin

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.

Subcutaneous injection
HormoneIn Clinical Trials

Kisspeptin

A neuropeptide encoded by the KISS1 gene that serves as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin activates GPR54 (KISS1R) on GnRH neurons, stimulating gonadotropin-releasing hormone secretion and subsequent LH and FSH release. It plays a critical role in puberty onset, reproductive function, and fertility regulation.

Intravenous, Subcutaneous injection
HormoneIn Clinical Trials

MK-677 (Ibutamoren)

An orally bioavailable, non-peptide growth hormone secretagogue that mimics the action of ghrelin at the GHS-R1a receptor. MK-677 stimulates sustained GH and IGF-1 elevation for up to 24 hours after a single oral dose without affecting cortisol levels. Its long duration of action and oral availability distinguish it from injectable GH secretagogues, and it preserves the pulsatile pattern of GH release.

Oral
ReproductiveIn Clinical Trials

Carbetocin

A long-acting synthetic analog of oxytocin with a modified disulfide bridge that confers resistance to enzymatic degradation. Carbetocin has a half-life of approximately 40 minutes compared to 3-5 minutes for oxytocin, providing sustained uterotonic activity after a single injection. It selectively binds oxytocin receptors in the myometrium, promoting uterine contraction and reducing postpartum blood loss.

Intravenous, Intramuscular injection
LongevityIn Clinical Trials

NAD+ Precursors (NMN)

Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism, DNA repair (via sirtuins and PARPs), and circadian rhythm regulation. NAD+ levels decline with age, and NMN supplementation restores tissue NAD+ levels, activating SIRT1-mediated pathways that regulate mitochondrial biogenesis and oxidative stress resistance.

Oral, Intravenous, Sublingual
LongevityIn Clinical Trials

SS-31 (Elamipretide)

A mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that selectively concentrates in the inner mitochondrial membrane by binding to cardiolipin. SS-31 stabilizes cytochrome c interactions with cardiolipin, optimizing electron transport chain efficiency and reducing mitochondrial reactive oxygen species (ROS) production. It restores mitochondrial bioenergetics in aged and diseased tissues without acting as a conventional antioxidant scavenger.

Subcutaneous injection, Intravenous
GastrointestinalIn Clinical Trials

Larazotide

A synthetic octapeptide derived from Vibrio cholerae zonula occludens toxin that acts as a tight junction regulator. Larazotide acetate modulates intestinal permeability by preventing zonulin-mediated opening of tight junctions between enterocytes. By reducing paracellular permeability, it aims to prevent gluten peptide translocation across the intestinal barrier in celiac disease, reducing the immune-mediated inflammatory response triggered by gluten exposure.

Oral
PainIn Clinical Trials

ARA-290

A synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.

Subcutaneous injection, Intravenous